Please login to the form below
Glybera
This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.
Bluebird puts €1.57m price on gene therapy Zynteglo
Zynteglo won't be the first ever 1m plus gene therapy launched in Europe - that distinction went to UniQure's rare disease treatment Glybera, which was launched in 2012.
Latest news
-
UniQure gets speedy US review for Huntington’s gene therapy
a-year Glybera back in 2012.
-
J&J bolsters gene therapy unit with $100m MeiraGTx deal
In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons.
-
AZ makes gene therapy move with 4DMT alliance
While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut
-
UniQure’s starts pivotal haemophilia B gene therapy trial
UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
-
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum
Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
UniQure gets speedy US review for Huntington’s gene therapy
J&J bolsters gene therapy unit with $100m MeiraGTx deal
AZ makes gene therapy move with 4DMT alliance
UniQure’s starts pivotal haemophilia B gene therapy trial
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum
More from news
Approximately 3 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Assessing the risks in annuity pricing models
Three others (ChondroCelect, PROVENGE and Glybera) were withdrawn, partly due to challenges associated with reimbursement.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera.
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
-
Health on instalment
Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
-
Rare diseases: meeting the challenge
Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
Assessing the risks in annuity pricing models
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Bluebird Bio: on the cusp of a gene therapy revolution
Health on instalment
Rare diseases: meeting the challenge
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase
Basilea's Hans Christian Rohde takes up commercial role at uniQure
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Solaris Health looks at the gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
Solaris Health looks at the gene therapy revolution
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
No results were found
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
